{"id":2062,"date":"2021-08-20T14:18:25","date_gmt":"2021-08-20T18:18:25","guid":{"rendered":"https:\/\/lifescivoice.com\/?p=2062"},"modified":"2021-08-20T14:32:17","modified_gmt":"2021-08-20T18:32:17","slug":"bayer-relying-on-kerendia-to-drive-pharma-business-growth-with-five-kidney-indications-in-sight","status":"publish","type":"post","link":"https:\/\/lifescivoice.com\/bayer-relying-on-kerendia-to-drive-pharma-business-growth-with-five-kidney-indications-in-sight\/","title":{"rendered":"Bayer relying on Kerendia to drive pharma business growth with five kidney indications in sight"},"content":{"rendered":"\n

The pharma division of German healthcare group<\/a>, Bayer, is counting on its recently approved drug, Kerendia, among some other potential blockbuster drugs, which the Bayer pharma chief, Stefan Oelrich, has entitled as \u201cthe kidney medicine\u201d.\u00a0 The company has predicted that the said drug could generate over \u20ac1 billion in its peak sales.<\/p>\n\n\n\n

For Kerendia, Oelrich said to the investors, \u201cWe really think that we have the kidney medicine\u2026 The kidney medicine<\/a> means we have the product that is designed to treat kidney with five different indications.\u201d<\/p>\n\n\n\n

The drug was approved last month which can be used as the treatment<\/a> for reducing risks of kidney function decline, hospitalization of patients with heart failure due to chronic kidney disease, final-stage kidney disease, cardiovascular death and non-fatal heart attacks, all associated with Type-2 diabetes.<\/p>\n\n\n\n

Being an adversary to mineralocorticoid receptors, Kerendia has similar mechanism of action with similar heart drugs like Viatris\u2019 Inspra. <\/p>\n\n\n\n

SGLT2 inhibitors, such as AstraZeneca\u2019s Farxiga, are also being approved as the treatment for different kidney and\/or heart-related ailments. As noted by one of the analysts, SGLT2s are cheaper in price as compared to Kerendia.<\/p>\n\n\n\n

Farxiga has been widely used as a diabetes drug so Oelrich pleaded that the pricing of the drugs must not be compared. \u201cThis is not a diabetes drug,\u201d he said of Kerendia.     <\/p>\n\n\n\n

Kerendia\u2019s launch took place after Bayer\u2019s pharma unit recovered from the deceleration of firm\u2019s operations due to the pandemic. Bayer witnessed a 16.2% growth in sales from its pharmaceutical<\/a> unit at constant currencies, to \u20ac4.49 billion ($5.32 billion), in second quarter.<\/p>\n\n\n\n

Owing to its strong show, the company is now expecting a 6% growth in pharma instead of the prior estimate of 4%, this year.<\/p>\n\n\n\n

The sales for the entire company upsurged by 12.9%, to \u20ac10.85 billion, in the second quarter. The healthcare group<\/a> is now projecting its yearly revenues to be nearly \u20ac44 billion, up from the previous \u20ac42- \u20ac43 billion.<\/p>\n","protected":false},"excerpt":{"rendered":"

The pharma division of German healthcare group, Bayer, is counting on its recently approved drug, Kerendia, among some other potential blockbuster drugs, which the Bayer pharma chief, Stefan Oelrich, has entitled as \u201cthe kidney medicine\u201d.\u00a0 The company has predicted that the said drug could generate over \u20ac1 billion in its peak sales. For Kerendia, Oelrich […]<\/p>\n","protected":false},"author":1,"featured_media":2064,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[81,497,498],"class_list":{"0":"post-2062","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-research-development","8":"tag-bayer","9":"tag-kerendia","10":"tag-kidney-disease"},"_links":{"self":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts\/2062","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/comments?post=2062"}],"version-history":[{"count":0,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts\/2062\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/media\/2064"}],"wp:attachment":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/media?parent=2062"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/categories?post=2062"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/tags?post=2062"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}